Medical treatment of non-alcoholic steatohepatitis.
There is no proven medical treatment of non-alcoholic steatohepatitis (NASH). Most prior therapeutic trials have had methodologic limitations. Insulin sensitizers are the more promising therapeutic candidates among categories that include antioxidants, lipid-lowering agents, and antiobesity drugs. The future will see the evaluation of novel agents and a comprehensive treatment strategy that addresses the risk factors for the metabolic syndrome. This article reviews the current status of medical management options for NASH.
Kadayifci
Abdurrahman
A
Division of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143-0538, USA. kadayifci@gantep.edu.tr
Merriman
Raphael B
RB
Bass
Nathan M
NM
D000975:Antioxidants / Q000627:therapeutic use; D019610:Cytoprotection; D005234:Fatty Liver / Q000150:complications / Q000628:therapy*; D006505:Hepatitis / Q000150:complications / Q000628:therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D015431:Weight Loss
D000975:Antioxidants; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents